To accelerate the high-quality development of Xiamen’s biopharmaceutical industry, improve the industrial, innovation, capital, talent, and service chains, optimize the industrial ecosystem, and make every effort to build a distinctive national-level biopharmaceutical industrial cluster, in accordance with the “Notice of the People’s Government of Fujian Province on Issuing the Implementation Plan for Accelerating the High-Quality Development of the Biopharmaceutical Industry in Fujian Province” (Min Zheng [2022] No. 10),the "Notice of the Fujian Provincial Department of Industry and Information Technology and 10 Other Departments on Issuing Several Measures to Further Implement the Implementation Plan for Accelerating the High-Quality Development of the Biomedical Industry in Fujian Province" (Min Gongxin Gui [2023] No. 7), and other relevant regulations, and in light of the actual conditions of this city, the following measures are proposed.
I. Enhancing R&D and Innovation Capabilities
(1) Supporting the R&D of Innovative Products
Innovative drugs, modified new drugs, and generic drugs that undergo clinical trials and are commercialized within the city will be granted rewards in stages based on their R&D progress.
For innovative drugs (Class 1 biological products, chemical drugs, traditional Chinese medicines, and natural medicines) commercialized in this city that have completed preclinical research, a reward of up to 4 million yuan will be granted, based on a standard of up to 40% of R&D investment; for those that have completed Phase I, II, or III clinical trials, rewards of up to 10 million yuan, 20 million yuan, and 30 million yuan, respectively, will be granted based on a standard of up to 40% of R&D investment;For those that have completed overseas clinical studies, a reward of up to 3 million yuan will be granted, based on a standard of no more than 40% of R&D expenditures. For improved new drugs (Category 2 biological products, chemical drugs, traditional Chinese medicines, and natural medicines) and traditional Chinese medicine compound preparations based on ancient classic formulas that have been commercialized in this city and have completed preclinical studies, a reward of up to 1 million yuan will be granted, based on a standard of no more than 20% of R&D expenditures;For the completion of Phase I, II, and III clinical trials, rewards of up to 3 million yuan, 8 million yuan, and 15 million yuan, respectively, shall be granted based on a standard of up to 20% of R&D investment; for the completion of overseas clinical research, a reward of up to 2 million yuan shall be granted based on a standard of up to 20% of R&D investment.For industrialization projects involving key-introduced innovative drugs and improved new drugs, upon completion of the product transfer procedures, rewards may be granted in accordance with the above policies for clinical research conducted prior to introduction (excluding preclinical research). The annual support amount for a single enterprise under these policies shall not exceed 100 million yuan. Government-guided funds, such as municipal industrial investment funds and science and technology innovation and entrepreneurship guidance funds, are encouraged to invest in research projects at all clinical stages.
For generic drug products that are the first in the country to pass, among the first three to pass, or that pass (including those deemed to have passed) the consistency evaluation of quality and efficacy, one-time rewards of up to 3 million yuan will be granted, based on standards of up to 40%, 30%, and 20% of the evaluation costs, respectively. The annual support limit for a single enterprise shall not exceed 10 million yuan.
(Responsible Units: Municipal Science and Technology Bureau, Municipal Finance Bureau)
(2) Support for the Industrialization of Innovative Products
For innovative drugs (including Class 1 biological products, chemical drugs, and traditional Chinese medicines), improved new drugs (including Class 2 biological products, chemical drugs, and traditional Chinese medicines), and generic drugs (including Class 3 and Class 4 biological products and chemical drugs) that have obtained a drug registration certificate and achieved industrialization for the first time, with cumulative sales revenue reaching 1 million yuan, a reward of 10 million yuan, 5 million yuan, or 3 million yuan will be granted per product, respectively, based on category.with the annual support limit for a single enterprise not exceeding 30 million yuan.
For Class II and Class III medical devices that have obtained registration certificates and are commercialized for the first time in this city, with cumulative sales revenue reaching 500,000 yuan, a reward of 400,000 yuan and 1,000,000 yuan per product will be granted respectively according to the category; the annual support limit for a single enterprise shall not exceed 5,000,000 yuan.For Class III medical devices that have entered the National Special Review Procedure for Innovative Medical Devices and obtained a product registration certificate, and are industrialized in this city for the first time, a one-time reward of 2 million yuan will be granted per product. For major projects among these, upon evaluation, a reward of up to 6 million yuan per product may be granted. For health foods, special cosmetics, and foods for special medical purposes that have obtained registration certificates and are industrialized in this city for the first time, a one-time reward of 600,000 yuan will be granted per product.
(Responsible Units: Municipal Science and Technology Bureau, Municipal Finance Bureau)
(3) Support for Overseas Registration and Certification of Innovative Products
For innovative drugs and modified new drugs that have obtained registration approvals from ICH member countries or passed World Health Organization Prequalification (WHO PQ), a one-time reward of 3 million yuan or 1.5 million yuan per variety will be granted based on category, with a maximum of 6 million yuan per enterprise annually.For medical device products that obtain international registration or certification in the European Union, the United States, the United Kingdom, Japan, Australia, Brazil, or Russia for the first time, a one-time reward of 300,000 yuan and 500,000 yuan will be granted per registration unit corresponding to domestic Class II and Class III medical devices, respectively, with a maximum of 5 million yuan per enterprise per year.
(Responsible Units: Municipal Science and Technology Bureau, Municipal Finance Bureau)
(IV) Supporting Major Scientific and Technological Innovation
Focusing on life and health needs, we will organize and carry out basic and applied research, implement major science and technology projects, and encourage and support joint research and development among industry, academia, research institutions, and medical institutions. For enterprises undertaking national major projects such as the National Major New Drug Innovation Program and the National Key Research and Development Program in the field of biomedicine, matching funds will be provided at a 1:1 ratio based on actual national funding, with the total funding from national, provincial, and municipal sources not exceeding the total project investment.Industry associations, enterprises, public institutions, and social organizations are encouraged to serve as drafting entities for the formulation of international, national, industry, and group standards, and will be provided with corresponding support in accordance with regulations.
(Responsible Units: Municipal Science and Technology Bureau, Finance Bureau, Market Regulation Bureau)
(5) Building Science and Technology Innovation Platforms
Support universities, research institutes, and enterprises in building major innovation platforms closely related to the development of the biopharmaceutical industry. Provide a subsidy of 10 million yuan each for newly recognized National Key Laboratories, National Engineering Research Centers, National Technology Innovation Centers, National Industrial Innovation Centers, and National Manufacturing Innovation Centers; provide a subsidy of 5 million yuan for newly recognized National Enterprise Technology Centers and National Technology Innovation Demonstration Enterprises.
(Responsible Units: Municipal Science and Technology Bureau, Development and Reform Commission, Industry and Information Technology Bureau, Finance Bureau)
(6) Establishing Innovative Research Institutions
Focusing on key areas such as innovative drugs, high-end medical devices, and biological therapy technologies, we will establish several influential innovation research institutions. Those meeting the city’s criteria for recognition as new-type R&D institutions will be granted rewards in accordance with relevant regulations.
(Responsible Units: Municipal Science and Technology Bureau, Municipal Finance Bureau)
II. Strengthening the Competitiveness of Industrial Development
(7) Encouraging Enterprises to Improve Quality and Efficiency, and Grow Stronger
Leverage the leading role of flagship biopharmaceutical enterprises in the industrial chain to cultivate “gazelle enterprises” and “single-champions” in the biopharmaceutical sector, fostering a group of leading enterprises with international competitiveness. Eligible enterprises will be granted rewards in accordance with relevant regulations.
(Responsible Units: Municipal Bureau of Industry and Information Technology, Municipal Finance Bureau)
(8) Promoting the Commercialization of Scientific and Technological Achievements
Organize and implement a series of industry-academia-research collaborative innovation projects that effectively strengthen, supplement, and extend the biopharmaceutical industry chain and demonstrate significant leading and driving effects. Accelerate the improvement of mechanisms for the ownership and benefit-sharing of scientific and technological achievements and intellectual property rights, and increase the proportion of revenue from achievement transformation for core teams and principal inventors. Support enterprises in purchasing and transforming domestic and international scientific and technological achievements. For enterprises that purchase major biopharmaceutical scientific and technological achievements and achieve industrialization within the city, a subsidy of up to 30% of the actual amount paid for the technology transaction will be provided, with a maximum of 3 million yuan.
(Responsible Units: Municipal Science and Technology Bureau, Municipal Finance Bureau)
(9) Projects to Develop the Headquarters Economy
For well-known domestic and international biopharmaceutical enterprises, such as those listed on the Fortune Global 500 or China’s Top 500, that establish regional headquarters or functional headquarters (such as R&D centers or operational centers) in Xiamen, support will be provided in accordance with the city’s regulations on supporting the development of the headquarters economy.
(Responsible Units: Municipal Development and Reform Commission, Municipal Finance Bureau)
(10) Cultivating New Business Models and Formats
We will foster the development of the biopharmaceutical service industry. For newly established industrial application platforms in the city, such as Contract Research Organizations (CROs), Contract Manufacturing Organizations (CMOs), and Contract Development and Manufacturing Organizations (CDMOs), subsidies of up to 40% of fixed-asset investment, with a maximum of 50 million yuan, will be provided. Special support will be granted to eligible major projects in accordance with regulations. (Responsible Units: Municipal Bureau of Industry and Information Technology, Municipal Science and Technology Bureau, Municipal Finance Bureau)
Support enterprises in conducting R&D innovation and the transfer and commercialization of results in accordance with the Marketing Authorization Holder (MAH) system for pharmaceuticals and the Medical Device Registrant system. For biopharmaceutical enterprises engaged in contract manufacturing under the MAH system for pharmaceuticals or the Medical Device Registrant system, the contract manufacturer (where the contracting parties are unaffiliated and have no investment relationship) shall receive funding of up to 10% of the annual actual new contract transaction value, with a maximum of 5 million yuan, for each individual product.The annual funding for a single enterprise shall not exceed 10 million yuan. (Responsible Units: Municipal Science and Technology Bureau, Market Regulation Bureau, Finance Bureau)
Contract research organizations (CROs) in the biopharmaceutical sector with annual operating revenues of 20 million yuan or more that provide services to non-affiliated biopharmaceutical enterprises or institutions with no investment relationship shall be granted a reward of up to 10% of the actual service amount, with a maximum of 5 million yuan per enterprise. (Responsible Units: Municipal Science and Technology Bureau, Municipal Finance Bureau)
(11) Supporting the Innovative Development of Traditional Chinese Medicine
Promote collaborative innovation among industry, academia, and research in traditional Chinese medicine (TCM), support the establishment of TCM clinical research centers, explore new clinical diagnostic and treatment methods and technologies, and facilitate the translation of TCM clinical research into practical applications. (Responsible Units: Municipal Science and Technology Bureau, Health Commission, Finance Bureau)
Develop a quality standards system for Chinese herbal medicines, and support the construction of high-quality production and cultivation bases for Chinese herbal medicines as well as testing platforms for authentic regional herbal medicines. Support the establishment of a traceability system for Chinese herbal decoction pieces, as well as the research, development, industrialization, and clinical application of Chinese herbal medicines and Chinese herbal formula granules. Establish an industrial chain development model where the cultivation and breeding of major Chinese herbal medicine varieties take place outside Xiamen, while the research, development, production, distribution, and sales of related products occur within Xiamen.(Responsible Units: Municipal Bureau of Agriculture and Rural Affairs, Municipal Bureau of Urban Planning and Landscape, Market Regulation Bureau, Health Commission, Science and Technology Bureau)
III. Optimizing the Industrial Ecosystem
(12) Optimizing Intellectual Property Services
Conduct priority examination and coordinated protection of invention patents in key technological fields of the biopharmaceutical industry, and strive to establish a local intellectual property protection center. Encourage intellectual property owners in the biopharmaceutical industry to contribute intellectual property as equity, and explore the establishment of a market-based risk compensation mechanism for intellectual property pledge financing.
(Responsible Units: Municipal Market Regulation Bureau, Financial Regulation Bureau, Xiamen Securities Regulatory Bureau, Xiamen Regulatory Bureau of the National Financial Supervisory Administration)
(13) Supporting Innovative Demonstration Applications
Encourage medical institutions to procure innovative products; procurement of such products by public medical institutions shall not be included in the institutions’ restrictive performance evaluation indicators. Develop and dynamically update a catalog of innovative biopharmaceutical products, and assist in efforts to have them included in the National Medical Insurance Drug List. Establish a face-to-face mechanism involving health authorities, medical insurance agencies, and enterprises to support the entry of high-quality innovative products into medical institutions in Xiamen. (Responsible Units: Municipal Health Commission, Medical Insurance Bureau, Science and Technology Bureau, Market Regulation Bureau)
Strengthen the promotion and procurement of the first-of-its-kind medical devices. For medical devices recognized as the first-of-its-kind major technical equipment in China, provide rewards in accordance with relevant regulations. (Responsible Units: Municipal Bureau of Industry and Information Technology, Science and Technology Bureau, Finance Bureau)
(14) Promote Market Expansion for Innovative Products
Increase efforts to apply and promote innovative products developed by enterprises for the screening, prevention, and treatment of major diseases and major infectious diseases. Support clinical application research of innovative pharmaceuticals and medical devices in local medical institutions, and ensure newly approved products are promptly listed on the provincial joint price-capped transparent procurement platform for pharmaceuticals and medical devices.Promote the rational application of newly listed products; optimize procurement processes—including bidding and tendering—for innovative pharmaceuticals, medical devices, and consumables entering hospitals; and guide local medical institutions to promptly include listed products in their institutional procurement catalogs. Promote commercial insurance as a supplement to medical insurance to build a diversified protection system; support commercial insurance institutions in developing commercial health insurance products with coverage extending to the application of new technologies, new drugs, and new medical devices.(Responsible Units: Municipal Health Commission, Medical Insurance Bureau, Market Regulation Bureau, Finance Bureau, Financial Regulatory Bureau)
Encourage pharmaceutical companies to expand into overseas markets. Support industry associations in organizing biopharmaceutical companies to participate in well-known domestic professional exhibitions, and provide incentives in accordance with relevant regulations. (Responsible Units: Municipal Bureau of Industry and Information Technology, Municipal Finance Bureau)
(15) Strengthen the Supply of Clinical Resources
Encourage medical institutions to actively apply for accreditation as clinical trial sites. Clinical research beds at accredited institutions will not be included in the institution’s total bed count and will not be subject to performance evaluations regarding bed profitability, turnover rate, or utilization rate. A reward of 200,000 yuan will be granted for each new specialized department for drug clinical trials (GCP) established by a medical institution, with a maximum annual reward of 1 million yuan per institution. (Responsible Units: Municipal Science and Technology Bureau, Health Commission, Finance Bureau)
Support medical institutions in serving the biopharmaceutical industry. For clinical trials conducted by medical institutions that meet the eligibility criteria, a reward of 10% of the actual service revenue will be granted, with a maximum of 2 million yuan per medical institution. (Responsible Units: Municipal Science and Technology Bureau, Municipal Finance Bureau)
Establish a city-wide clinical research ethics review collaboration alliance to promote multi-center ethics review coordination and explore the establishment of a mutual recognition system for multi-center clinical research ethics review results. Encourage registered medical institutions to establish and improve review mechanisms, optimize procedures for clinical trial project initiation, ethics review, and protocol review, expedite project launch, and accelerate the clinical trial process for product R&D.Medical personnel at healthcare institutions are encouraged to participate in clinical application research. Upon the commercialization of scientific and technological achievements resulting from their duties, cash rewards granted by the institution responsible for the achievement to personnel who made significant contributions to its completion and commercialization shall be included in the institution’s total performance-based salary pool. However, such rewards shall not be subject to the approved total performance-based salary limit, shall not be used as the basis for determining the total performance-based salary for the following year, and shall not be included in the social insurance contribution base.Promote the establishment and improvement of incentive mechanisms for career advancement, professional title promotion, and compensation for clinical trial investigators and staff in clinical trial management departments within medical institutions to enhance the enthusiasm of medical personnel in conducting clinical trials. (Responsible Units: Municipal Health Commission, Human Resources and Social Security Bureau, Science and Technology Bureau, Tax Bureau)
Improve the clinical research support platform system. In accordance with the National Health Commission’s mechanism for the open sharing of health and medical big data, research standards for the graded and categorized opening of health and medical big data. While ensuring data security, promote the establishment of an operable and controllable system for the sharing and opening of health and medical big data. Explore the establishment of a biological sample sharing mechanism to increase the effective supply of biological samples for clinical trials and accelerate the industrialization of R&D innovations. (Responsible Units: Municipal Health Commission, Science and Technology Bureau)
Enhance innovation capabilities in medical-engineering integration. Establish a mechanism for medical-engineering collaboration, support the construction of medical-engineering collaborative innovation and R&D platforms as well as digital management platforms for clinical trials; support qualified medical institutions in building research-oriented hospitals; support research-oriented hospitals in conducting compassionate use of investigational drugs for clinical trials; leverage the roles of professional societies, industry associations, and industrial alliances to build platforms for pharmaceutical companies to engage with medical institutions, guiding enterprises to proactively communicate and collaborate with medical institutions, thereby fostering mutual trust and promoting joint development.(Responsible Units: Municipal Health Commission, Science and Technology Bureau, Market Regulation Bureau, Finance Bureau)
(16) Support the Development of Clinical Medical Research Centers
Municipal-level clinical medical research centers that pass acceptance inspections will receive a subsidy of 2 million yuan, and those rated excellent will receive 1.5 million yuan in support; provincial-level clinical medical research centers that pass acceptance inspections will receive a subsidy of 2 million yuan (not cumulative with municipal-level centers), and those rated excellent will receive 1.5 million yuan in support; Fujian Provincial Branches of National Clinical Medical Research Centers that obtain accreditation and complete construction will receive a subsidy of 4 million yuan, and those rated excellent will receive 2 million yuan in support;For those that have obtained the qualification for a National Clinical Medical Research Center, the subsidy will be topped up to 10 million yuan.
(Responsible Units: Municipal Science and Technology Bureau, Health Commission, Finance Bureau)
(17) Enhance Registration, Certification, and Testing Capabilities
Strengthen coordination with national and provincial drug regulatory authorities, optimize the review and approval processes for pharmaceuticals and medical devices, provide guidance and support for preliminary product registration and technical reviews, recruit professional talent and provide vocational training for industry regulatory teams, enhance specialized service capabilities, and create a high-quality, convenient environment for product registration and application.Strengthen the development of biomedical testing and inspection capabilities within the city. Support the Xiamen Food and Drug Quality Inspection Institute in establishing a high-level comprehensive testing laboratory for pharmaceuticals and medical devices, and expand its testing capabilities and qualifications for medical devices. Encourage leading enterprises with strong capabilities to participate in the establishment of third-party testing and inspection service institutions, thereby enhancing the city’s regional influence and driving force in the field of biomedical testing and inspection.
(Responsible Units: Municipal Market Regulation Bureau, Science and Technology Bureau, Haicang District Government)
(18) Leverage the Synergy of the “Dual Pilot Zones”
Optimize approval procedures for sanitary and quarantine inspections of special items. Implement a “single assessment, batch import” approach for the import of the same type of special item by the same pilot enterprise to improve the efficiency of special item approval services and enhance the functionality of the Xiamen Public Service Platform for the Import and Export of Special Biomedical Materials.
(Responsible Units: Xiamen Customs, Free Trade Zone Commission, Municipal Science and Technology Bureau, Haicang District Government)
(19) Strengthen the Investment and Financing System
Leverage the roles of the Xiamen Industrial Investment Fund and the Science and Technology Achievement Transformation and Industrialization Fund to encourage the establishment of funds targeting the biopharmaceutical sector; encourage industry enterprises to jointly initiate the establishment of funds, focusing on early- and mid-stage, as well as startup-level innovative and entrepreneurial enterprises in the biopharmaceutical sector. Encourage high-quality biopharmaceutical enterprises to fully utilize domestic and international multi-tiered capital markets for listing and financing, and provide corresponding incentives in accordance with regulations.Encourage various financial institutions in the city to include the biopharmaceutical industry within the scope of government-bank-enterprise cooperation and support, and improve the investment and financing service system. Encourage government-backed financing guarantee institutions to provide credit enhancement support.
(Responsible Units: Municipal Financial Regulatory Bureau, Finance Bureau, Science and Technology Bureau, Xiamen Securities Regulatory Bureau)
(20) Improve the Industrial Talent Support System
Increase support for talent in the biopharmaceutical sector. Provide eligible talent with support in housing, medical care, children’s education, spousal relocation, and entrepreneurship assistance, and include biopharmaceutical talent in the city’s local leading talent policies for support.Establish evaluation criteria for high-end talent in Xiamen’s biopharmaceutical industry. For R&D, production, and management personnel recruited by biopharmaceutical enterprises within the past three years, those confirmed through review will be granted a subsidy of up to 800,000 yuan, disbursed over three years in the ratio of 40%, 30%, and 30%. Encourage local universities and research institutes to strengthen talent cultivation in relevant disciplines in line with industry needs, support customized talent training programs, organize open training courses, and build a well-structured talent pipeline for the biopharmaceutical industry.We will deepen the reform of professional title evaluation in the biopharmaceutical industry, adopting a demand-oriented approach to broaden career advancement pathways for specialized professionals.
(Responsible Units: Municipal Science and Technology Bureau, Municipal Party Committee Organization Department, Municipal Finance Bureau, Human Resources and Social Security Bureau, Development and Reform Commission, Housing Bureau, Industry and Information Technology Bureau, Education Bureau, district governments, and the Torch High-Tech Zone Administrative Committee)
(21) Rationally Plan the Spatial Layout of Industrial Development
Coordinate the innovative development layout of the biopharmaceutical industry. In accordance with the guidelines for industrial spatial layout and the planning for industrial land use, establish a spatial layout characterized by “one core, multiple nodes, distinct features, and complementary development.” Prioritize the construction of the Xiamen Biopharmaceutical Port and the city’s planned biopharmaceutical industrial parks, fostering the development of biopharmaceutical industrial parks that integrate R&D innovation, business incubation, and high-end manufacturing.(Responsible Units: Municipal Development and Reform Commission, Municipal Bureau of Industry and Information Technology, Municipal Science and Technology Bureau, Municipal Bureau of Natural Resources and Planning, district governments, and Torch High-Tech Zone Management Committee)
Encourage universities, research institutes, and leading enterprises to establish or jointly build innovation and entrepreneurship incubation parks and bases to enhance the capacity to support industrial innovation projects. Deepen the integrated park development model of “industrial parks + new-type incubators + industrial funds + industrial alliances” to enhance the sustainable development capabilities of industrial parks. (Responsible Units: Municipal Science and Technology Bureau, Development and Reform Commission, Bureau of Resources and Planning; district governments; Torch Management Committee)
(22) Promote the Integrated Development of Cross-Strait Biomedical and Health Industries
Deepen cooperation with Taiwan in fields such as biomedicine, precision diagnostics, smart healthcare, traditional Chinese medicine, health foods, and cosmetics, with a focus on introducing new biomedical technologies and innovative medical device projects from Taiwan. Engage in exchanges and integration with Taiwanese medical institutions, biomedical enterprises, research institutes, and the health and beauty industry to promote a regular exchange mechanism between the two regions in the field of biomedicine.Support the alignment of traditional Chinese medicine industrial chains across the strait, develop standardization and industrialization of distinctive Fujian-Taiwan medicinal herbs, and focus on researching the pharmacological properties and clinical efficacy of authentic and renowned medicinal herbs from Fujian and Taiwan. Leverage the city’s regional advantages in cross-strait relations to conduct pilot programs in the field of cell and gene therapy, and promote the integrated development of the cell and gene therapy industries across the strait.(Responsible Units: Municipal Science and Technology Bureau, Taiwan, Hong Kong, and Macao Affairs Office, Market Regulation Bureau, Health Commission, Industry and Information Technology Bureau, Development and Reform Commission; district governments; Torch Development Zone Management Committee)
IV. Strengthening Organizational Support and Services
(23) Strengthen Municipal-Level Coordination
Establish more effective communication and coordination mechanisms. Building upon the municipal industrial development leading group, establish a joint conference system and an entrepreneur dialogue mechanism to focus on coordinating and resolving major issues in industrial and enterprise development. Strengthen coordination between the municipal and district levels to promote the clustered development of industries.
(Responsible Units: Municipal Science and Technology Bureau, Development and Reform Commission, Finance Bureau, Industry and Information Technology Bureau, Health Commission, Medical Insurance Bureau, Market Regulation Bureau, Financial Regulatory Bureau, Commerce Bureau, Xiamen Regulatory Bureau of the National Financial Supervisory Administration, district governments, and Torch Administrative Committee)
(24) Supporting the Development of Industry Organizations
Strengthen the development of organizations such as the Biomedical Industry Alliance and industry associations, support them in conducting industry planning, trend analysis, and statistical monitoring, and leverage their functions as bridges and think tank platforms. Encourage industry organizations to engage in industry-academia-research collaboration, professional title evaluation, technical consulting services, and standard-setting. Support the hosting of national or specialized industrial forums, summits, exhibitions, and academic exchanges in Xiamen to foster a favorable development environment.
(Responsible Units: Municipal Science and Technology Bureau, Development and Reform Commission, Commerce Bureau)
V. Other Provisions
These measures primarily support research and development, production, and services in the fields of pharmaceuticals (including chemical drugs, biological products, traditional Chinese medicine, and natural products), high-end medical devices, advanced pharmaceutical equipment and materials, new types of service outsourcing, and digital medical (pharmaceutical) products.
The classification and definition rules for innovative drugs and modified new drugs will be adjusted in a timely manner in accordance with the drug registration classification standards issued by the National Medical Products Administration.
Funding under these measures will be allocated in accordance with the fiscal year budget. Where there is overlap with other similar provincial or municipal policies, the principle of “selecting the most favorable and highest-value option without duplication” shall apply. Each district may formulate relevant incentive measures based on local conditions.
The Xiamen Municipal Science and Technology Bureau, in conjunction with relevant departments, shall be responsible for interpreting these measures.
These measures shall take effect on November 20, 2023, and remain valid until December 31, 2026.
